ACADL: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 03:03, 17 March 2025
ACADL or Acyl-CoA Dehydrogenase, Long Chain is an enzyme that in humans is encoded by the ACADL gene. It is involved in the breakdown of long-chain fatty acids, a process that provides energy for the body. Mutations in this gene can lead to a variety of metabolic disorders, including lipid metabolism disorders and fatty acid oxidation disorders.
Function[edit]
The ACADL enzyme is part of a family of enzymes known as Acyl-CoA dehydrogenases. These enzymes catalyze the dehydrogenation of acyl-CoA derivatives in the metabolism of fatty acids and some amino acids. The enzyme encoded by this gene uses flavin adenine dinucleotide (FAD) as a cofactor to catalyze the initial step of the mitochondrial fatty acid beta-oxidation pathway.
Clinical significance[edit]
Mutations in the ACADL gene can lead to a deficiency in the ACADL enzyme, a condition known as ACADL deficiency or long-chain acyl-CoA dehydrogenase deficiency (LCAD deficiency). This is a rare inherited disorder that prevents the body from converting certain fats into energy. Symptoms can include hypoglycemia, muscle weakness, and cardiomyopathy.
Diagnosis and Treatment[edit]
Diagnosis of ACADL deficiency is typically made through a combination of clinical examination, biochemical testing, and molecular genetic testing. Treatment typically involves dietary management to avoid long periods of fasting, and in some cases, supplementation with medium-chain triglycerides.
See also[edit]
